510 related articles for article (PubMed ID: 29553053)
1. Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.
Dorff TB; Agarwal N
Asian J Androl; 2018; 20(3):215-220. PubMed ID: 29553053
[TBL] [Abstract][Full Text] [Related]
2. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
Gartrell BA; Coleman R; Efstathiou E; Fizazi K; Logothetis CJ; Smith MR; Sonpavde G; Sartor O; Saad F
Eur Urol; 2015 Nov; 68(5):850-8. PubMed ID: 26153564
[TBL] [Abstract][Full Text] [Related]
3. Management of bone metastases in prostate cancer: a review.
Bienz M; Saad F
Curr Opin Support Palliat Care; 2015 Sep; 9(3):261-7. PubMed ID: 26262831
[TBL] [Abstract][Full Text] [Related]
4. Targeting bone metastases in prostate cancer: improving clinical outcome.
Body JJ; Casimiro S; Costa L
Nat Rev Urol; 2015 Jun; 12(6):340-56. PubMed ID: 26119830
[TBL] [Abstract][Full Text] [Related]
5. New and emerging therapies for bone metastases in genitourinary cancers.
Saylor PJ; Armstrong AJ; Fizazi K; Freedland S; Saad F; Smith MR; Tombal B; Pienta K
Eur Urol; 2013 Feb; 63(2):309-20. PubMed ID: 23201471
[TBL] [Abstract][Full Text] [Related]
6. Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Winquist E;
Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):348-355. PubMed ID: 28169118
[TBL] [Abstract][Full Text] [Related]
7. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
Vignani F; Bertaglia V; Buttigliero C; Tucci M; Scagliotti GV; Di Maio M
Cancer Treat Rev; 2016 Mar; 44():61-73. PubMed ID: 26907461
[TBL] [Abstract][Full Text] [Related]
8. [Encounter of cancer cells with bone. Management of bone metastasis arising from prostate cancer].
Kamoto T
Clin Calcium; 2011 Mar; 21(3):465-71. PubMed ID: 21358069
[TBL] [Abstract][Full Text] [Related]
9. The role of bone-targeted therapies for prostate cancer in 2017.
Traboulsi SL; Saad F
Curr Opin Support Palliat Care; 2017 Sep; 11(3):216-224. PubMed ID: 28644302
[TBL] [Abstract][Full Text] [Related]
10. Bone targeted therapies in metastatic castration-resistant prostate cancer.
Rajpar S; Fizazi K
Cancer J; 2013; 19(1):66-70. PubMed ID: 23337759
[TBL] [Abstract][Full Text] [Related]
11. Pathologic fracture in patients with metastatic prostate cancer.
Gartrell BA; Saad F
Curr Opin Urol; 2014 Nov; 24(6):595-600. PubMed ID: 25166424
[TBL] [Abstract][Full Text] [Related]
12. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
Gartrell BA; Coleman RE; Fizazi K; Miller K; Saad F; Sternberg CN; Galsky MD
Eur Urol; 2014 Feb; 65(2):278-86. PubMed ID: 23706567
[TBL] [Abstract][Full Text] [Related]
13. Emerging therapies to prevent skeletal morbidity in men with prostate cancer.
Saylor PJ; Lee RJ; Smith MR
J Clin Oncol; 2011 Sep; 29(27):3705-14. PubMed ID: 21860001
[TBL] [Abstract][Full Text] [Related]
14. The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer.
Saad F; Sternberg CN; Mulders PFA; Niepel D; Tombal BF
Cancer Treat Rev; 2018 Jul; 68():25-37. PubMed ID: 29787892
[TBL] [Abstract][Full Text] [Related]
15. Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.
Picciotto M; Franchina T; Russo A; Ricciardi GRR; Provazza G; Sava S; Baldari S; Caffo O; Adamo V
Expert Opin Pharmacother; 2017 Jun; 18(9):899-908. PubMed ID: 28449621
[TBL] [Abstract][Full Text] [Related]
16. Revisiting the role of bone-modifying agents in the management of metastatic prostate cancer.
Cheung FY
Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():13-15. PubMed ID: 30489032
[TBL] [Abstract][Full Text] [Related]
17. Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer.
Miller K; Steger GG; Niepel D; Lüftner D
Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):461-472. PubMed ID: 29988100
[TBL] [Abstract][Full Text] [Related]
18. Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer.
Graff JN; Beer TM
Oncology (Williston Park); 2015 Jun; 29(6):416-23. PubMed ID: 26091674
[TBL] [Abstract][Full Text] [Related]
19. The Role of the Microenvironment in Prostate Cancer-Associated Bone Disease.
Turner CJ; Edwards CM
Curr Osteoporos Rep; 2016 Oct; 14(5):170-7. PubMed ID: 27566487
[TBL] [Abstract][Full Text] [Related]
20. Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review.
Jong JM; Oprea-Lager DE; Hooft L; de Klerk JM; Bloemendal HJ; Verheul HM; Hoekstra OS; van den Eertwegh AJ
Eur Urol; 2016 Sep; 70(3):416-26. PubMed ID: 26391636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
